Acción A048410 HYUNDAI BIOSCIENCE CO., LTD.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Hyundai Bioscience Co., Ltd.

Acciones

A048410

KR7048410005

Precio de cierre Korea S.E.
Otros sitios de cotización
 00:00:00 26/06/2024 		Varia. Cinco días. Varia. 1 de enero.
18.010 KRW -0,11 % Gráfico intradía de Hyundai Bioscience Co., Ltd. +1,75 % -31,00 %
20/05 Hyundai Bioscience Co., Ltd. Ltd. (KOSDAQ:A048410), CnPharm Co., Ltd. y Yeonjin Kim completaron la adquisición del 34,91% de ADM Korea Inc. (KOSDAQ:A187660) a Mobiis Co. (KOSDAQ:A250060). CI
16/05 Hyundai Bioscience Co. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 3 billion in funding
Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim completed the acquisition of 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd..
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 18 billion in funding from Sangsangin Investment & Securities Co.,Ltd., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank
Hyundai Bioscience's Antiviral for Dengue Fever to Enter Clinical Trials in Brazil
Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-Based Metabolic Anticancer Drug Targeting P53 Mutation Cancer
Hyundai Bioscience Announces Its Successful Result from A Preclinical Study of A Niclosamide-Based Oral Anticancer Drug to Treat Triple-Negative Breast Cancer
Hyundai Bioscience to Carry Out Global Clinical Tests Aimed At Treating All Serotypes of Dengue Virus Infection
Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd. for KRW 31 billion.
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Vector Inc. completed the acquisition of additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd.
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Vector Inc. agreed to acquire additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. for KRW 13.7 billion.
Hyundai Bioscience to request a fast track processing for its monkeypox treatment drug with the FDA
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Hyundai Bioscience Co., Ltd. Launches CP-COV03 Phase 2 Clinical Trials
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción A048410
  4. Noticias Hyundai Bioscience Co., Ltd.
  5. Otros idiomas